The ME/CFS Collaborative Research Center (previously known as the CFS Research Center) at Stanford University was established in 2014 and is part of the Stanford Genome Technology Center. Both centers are directed by Ronald W. Davis, PhD, Professor of Biochemistry and of Genetics at Stanford.
Throughout his career, Dr. Davis has conducted cutting edge, innovative, interdisciplinary research and technology development on cancer, immunology, genetics, infectious disease, novel drug development, and nanofabrication of diagnostic instruments. His emphasis has always been to increase accuracy and decrease cost. He has made significant contributions to research on numerous organisms, including bacteria, yeast, plants and humans.
Dr. Davis discovered a simple way to join together DNA from two organisms (“sticky ends”), and was the first to generate a hybrid DNA molecule that could replicate inside of cells (DNA cloning).
He developed most of the technology for the molecular genetics of yeast, which made it the most advanced model for conducting molecular genetics research.
Extended Big Data Study in Families STUDY AIM Beginning in 2016, the aim of this study was to extend the Severely ill Patient Study (SIPS) …
T cells and Immunology Study Aim Beginning in 2016, the aim of this study was to establish the role of T cells and the immune …
Severely iIl Patient Study Study Aim The aim of the Severely Ill Patient Study (SIPS), which started in 2015, was to conduct a comprehensive “Big …
Metabolic Trap Study STUDY AIM Beginning in 2018, the aim of this study was to test the hypothesis developed by Dr Phair that a crucial …
There is currently no biological test to diagnose Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) and as a result, diagnosing patients is a lengthy and costly process, constituting a fundamental impediment in patient care. This lag in diagnosis also erects barriers to research, complicating patient recruitment and potentially engaging a heterogeneous sample of patients with only superficially similar conditions.
Dr. Davis’s team is dedicated to developing inexpensive tests that can be easily used in a doctor’s office. Patients will be measured on multiple diagnostic platforms, enabling comparisons of efficacy to determine what combination of platforms would be most useful for diagnostic testing.
Mitochondrial Function Test TECHNOLOGY VALUE Demonstrates a significant difference between ME / CFS patients and healthy controls. LEAD INVESTIGATORS Julie Wilhelmy Ronald W. Davis, PhD UPDATES AND …
Magnetic Levitation Platform TECHNOLOGY VALUE This could be a very inexpensive and effective diagnostic test for ME / CFS. LEAD INVESTIGATORS Gozde Durmus, PhD Ronald W. Davis, …
Red Blood Cell Deformability in ME / CFS TECHNOLOGY VALUE This work has been accepted for publication in Clinical Hemorheology and Microcirculation and also has been accepted …
Developing Nanoneedle Technology TECHNOLOGY VALUE The technology will be optimized for easy clinical adoption and scaled up so that numerous FDA-approved drugs can be simultaneously …
Director
Ronald W. Davis, PhD, Professor of Biochemistry and Genetics, Stanford University School of Medicine; Director, Stanford Genome Technology Center; Director, Chronic Fatigue Syndrome Research Center at Stanford University; Director, Open Medicine Foundation ME/CFS Scientific Advisory Board.
Wenzhong Xiao, PhD
Mohsen Nemat-Gorgani, PhD
Peidong Shen, PhD
Laurel Crosby, PhD
Michael Jensen
Fereshteh Jahaniani, PhD
Gozde Durmus, PhD
Julie Wilhelmy
Alex Kashi
Anand Ramasubramanian, PhD
Amit Saha, PhD
Layla Cervantes
Ami Mac, MD
David Kaufman, MD
Bela Chheda, MD
Chris Armstrong, PhD
Katrina Hong
Anna Okumu
Ashley Haugen
Eric Shaqfeh, PhD
Mark M. Davis, PhD
Michael Sikora
Mike Snyder, PhD
Craig Heller, PhD
Lars Steinmetz, PhD
Jonas Bergquist, MD, PhD
Rahim Esfandyarpour, PhD
Ron Tompkins, MD, ScD
Curt Scharfe, MD
Robert Naviaux, MD, PhD
William Robinson, MD
Lucinda Bateman, MD
Jennifer Frankovich, MD
Open Medicine Foundation®
29302 Laro Drive, Agoura Hills, CA 91301 USA
Phone: 650-242-8669
Stay Informed
Be the first to hear our research news.
Subscribe Now.
